184 related articles for article (PubMed ID: 35870712)
41. CD63
Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
[TBL] [Abstract][Full Text] [Related]
42. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
43. Immune effects of CDK4/6 inhibitors in patients with HR
Scirocchi F; Scagnoli S; Botticelli A; Di Filippo A; Napoletano C; Zizzari IG; Strigari L; Tomao S; Cortesi E; Rughetti A; Marchetti P; Nuti M
EBioMedicine; 2022 May; 79():104010. PubMed ID: 35477069
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Bertolini I; Crucitta S; Fontanelli L; Rofi E; De Angelis C; Diodati L; Cavallero D; Gianfilippo G; Salvadori B; Fogli S; Falcone A; Scatena C; Naccarato AG; Roncella M; Ghilli M; Morganti R; Fontana A; Danesi R
Breast Cancer Res Treat; 2019 Nov; 178(1):57-62. PubMed ID: 31346846
[TBL] [Abstract][Full Text] [Related]
45. Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis.
Kubeczko M; Polakiewicz-Gilowska A; Świderska K; Leśniak A; Mianowska-Malec M; Łanoszka B; Chomik K; Grandys B; Lisovska N; Bobek-Billewicz B; Chmielik E; Jarząb M
Front Oncol; 2024; 14():1408664. PubMed ID: 38912058
[TBL] [Abstract][Full Text] [Related]
46. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
Adamia S; Bhatt S; Wen K; Chyra Z; Fell GG; Tai YT; Pioso MS; Abiatari I; Letai A; Dorfman DM; Hideshima T; Anderson KC
Leukemia; 2022 Apr; 36(4):1088-1101. PubMed ID: 35082402
[TBL] [Abstract][Full Text] [Related]
47. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.
Harbeck N; Bartlett M; Spurden D; Hooper B; Zhan L; Rosta E; Cameron C; Mitra D; Zhou A
Future Oncol; 2021 Jun; 17(16):2107-2122. PubMed ID: 33663223
[No Abstract] [Full Text] [Related]
48. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Wu X; Yang X; Xiong Y; Li R; Ito T; Ahmed TA; Karoulia Z; Adamopoulos C; Wang H; Wang L; Xie L; Liu J; Ueberheide B; Aaronson SA; Chen X; Buchanan SG; Sellers WR; Jin J; Poulikakos PI
Nat Cancer; 2021 Apr; 2(4):429-443. PubMed ID: 34568836
[TBL] [Abstract][Full Text] [Related]
49. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
50. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
51. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer.
Kim S; Armand J; Safonov A; Zhang M; Soni RK; Schwartz G; McGuinness JE; Hibshoosh H; Razavi P; Kim M; Chandarlapaty S; Yang HW
Cell Rep; 2023 Nov; 42(11):113198. PubMed ID: 37865915
[TBL] [Abstract][Full Text] [Related]
52. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
53. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
Kruse M; Smyth EN; Bowman L; Gautam S; Guimaraes CM; Nisbett AR; Fisher MD; Cui ZL; Sheffield KM; Kalinsky K
Breast Cancer Res Treat; 2023 Aug; 201(1):105-115. PubMed ID: 37310540
[TBL] [Abstract][Full Text] [Related]
54. Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
Chew SM; Ferraro E; Safonov A; Chen Y; Kelly D; Razavi P; Robson M; Seidman AD
Eur J Cancer; 2024 Jun; 207():114175. PubMed ID: 38896996
[TBL] [Abstract][Full Text] [Related]
55. Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Rao X; Chen Y; Beyrer J; Nash Smyth E; Morato Guimaraes C; Litchfield LM; Bowman L; Lawrence GW; Aggarwal A; Andre F
Clin Cancer Res; 2023 Sep; 29(17):3372-3383. PubMed ID: 37289194
[TBL] [Abstract][Full Text] [Related]
56. MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.
Ma J; Li L; Ma B; Liu T; Wang Z; Ye Q; Peng Y; Wang B; Chen Y; Xu S; Wang K; Dang F; Wang X; Zeng Z; Jian Y; Ren Z; Fan Y; Li X; Liu J; Gao Y; Wei W; Li L
Nat Commun; 2024 Feb; 15(1):1871. PubMed ID: 38424044
[TBL] [Abstract][Full Text] [Related]
57. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
58. Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature.
Franco R; Cao JQ; Yassa M; Hijal T
Curr Oncol; 2023 Jun; 30(6):5485-5496. PubMed ID: 37366898
[TBL] [Abstract][Full Text] [Related]
59. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.
Guo X; Chen H; Zhou Y; Shen L; Wu S; Chen Y
Expert Opin Investig Drugs; 2022 Sep; 31(9):933-944. PubMed ID: 35786092
[TBL] [Abstract][Full Text] [Related]
60. MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Vilgelm AE; Saleh N; Shattuck-Brandt R; Riemenschneider K; Slesur L; Chen SC; Johnson CA; Yang J; Blevins A; Yan C; Johnson DB; Al-Rohil RN; Halilovic E; Kauffmann RM; Kelley M; Ayers GD; Richmond A
Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]